Galectin Therapeutics (GALT) Competitors

Galectin Therapeutics logo
$2.91 -0.11 (-3.64%)
As of 11/17/2026 04:00 PM Eastern

GALT vs. IMTX, SNDX, LXRX, ALMS, and IRWD

Should you buy Galectin Therapeutics stock or one of its competitors? Galectin Therapeutics's main competitors and comparable companies include Immatics (IMTX), Syndax Pharmaceuticals (SNDX), Lexicon Pharmaceuticals (LXRX), Alumis (ALMS), and Ironwood Pharmaceuticals (IRWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Galectin Therapeutics compare to Immatics?

Immatics (NASDAQ:IMTX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Immatics presently has a consensus price target of $19.00, suggesting a potential upside of 202.07%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 278.01%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Immatics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

Galectin Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -533.26%. Galectin Therapeutics' return on equity of 0.00% beat Immatics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immatics-533.26% -52.54% -43.30%
Galectin Therapeutics N/A N/A -138.82%

64.4% of Immatics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 53.0% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Galectin Therapeutics had 7 more articles in the media than Immatics. MarketBeat recorded 8 mentions for Galectin Therapeutics and 1 mentions for Immatics. Galectin Therapeutics' average media sentiment score of 1.20 beat Immatics' score of -0.49 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immatics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Galectin Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Galectin Therapeutics has lower revenue, but higher earnings than Immatics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immatics$54.60M15.75-$222.26M-$1.95N/A
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A

Summary

Galectin Therapeutics beats Immatics on 8 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

11.7% of Galectin Therapeutics shares are held by institutional investors. 4.8% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 53.0% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Syndax Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Galectin Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -72.32%. Galectin Therapeutics' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals-72.32% -804.38% -34.93%
Galectin Therapeutics N/A N/A -138.82%

Galectin Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syndax Pharmaceuticals$172.35M4.81-$285.42M-$2.36N/A
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A

Syndax Pharmaceuticals currently has a consensus price target of $41.60, suggesting a potential upside of 352.17%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 278.01%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Syndax Pharmaceuticals is more favorable than Galectin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Galectin Therapeutics had 5 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 8 mentions for Galectin Therapeutics and 3 mentions for Syndax Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 1.20 beat Syndax Pharmaceuticals' score of 0.17 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Galectin Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Galectin Therapeutics beats Syndax Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Lexicon Pharmaceuticals?

Galectin Therapeutics (NASDAQ:GALT) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 278.01%. Lexicon Pharmaceuticals has a consensus price target of $5.80, suggesting a potential upside of 225.84%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Galectin Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A
Lexicon Pharmaceuticals$49.80M15.91-$50.34M-$0.14N/A

Galectin Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -161.80%. Galectin Therapeutics' return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Galectin TherapeuticsN/A N/A -138.82%
Lexicon Pharmaceuticals -161.80%-35.76%-24.53%

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 53.0% of Galectin Therapeutics shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Galectin Therapeutics had 6 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Galectin Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 1.20 beat Lexicon Pharmaceuticals' score of 0.96 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galectin Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lexicon Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Galectin Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Summary

Galectin Therapeutics and Lexicon Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Alumis currently has a consensus target price of $31.27, suggesting a potential upside of 546.13%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 278.01%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts plainly believe Alumis is more favorable than Galectin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Galectin Therapeutics has lower revenue, but higher earnings than Alumis. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alumis$24.05M26.05-$243.32M-$3.53N/A
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A

Galectin Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,844.54%. Galectin Therapeutics' return on equity of 0.00% beat Alumis' return on equity.

Company Net Margins Return on Equity Return on Assets
Alumis-5,844.54% -89.77% -71.50%
Galectin Therapeutics N/A N/A -138.82%

11.7% of Galectin Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 53.0% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alumis had 23 more articles in the media than Galectin Therapeutics. MarketBeat recorded 31 mentions for Alumis and 8 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 1.20 beat Alumis' score of -0.07 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alumis
2 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
5 Negative mention(s)
1 Very Negative mention(s)
Neutral
Galectin Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Alumis has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Summary

Galectin Therapeutics beats Alumis on 8 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

11.7% of Galectin Therapeutics shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 53.0% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Ironwood Pharmaceuticals currently has a consensus price target of $6.23, indicating a potential upside of 27.99%. Galectin Therapeutics has a consensus price target of $11.00, indicating a potential upside of 278.01%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ironwood Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57
Galectin Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Ironwood Pharmaceuticals has a net margin of 37.38% compared to Galectin Therapeutics' net margin of 0.00%. Galectin Therapeutics' return on equity of 0.00% beat Ironwood Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ironwood Pharmaceuticals37.38% -81.40% 42.69%
Galectin Therapeutics N/A N/A -138.82%

Ironwood Pharmaceuticals has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$296.15M2.72$24.02M$0.905.41
Galectin TherapeuticsN/AN/A-$30.84M-$0.43N/A

In the previous week, Galectin Therapeutics had 5 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 8 mentions for Galectin Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 1.20 beat Ironwood Pharmaceuticals' score of 0.79 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ironwood Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Galectin Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ironwood Pharmaceuticals has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

Summary

Ironwood Pharmaceuticals beats Galectin Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GALT vs. The Competition

MetricGalectin TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$198.89M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-8.5626.7134.3428.32
Price / SalesN/A15.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-1.464.184.453.72
Net Income-$30.84M-$24.15M$3.52B$393.10M
7 Day Performance-11.55%-7.81%-5.93%-5.77%
1 Month Performance-19.61%-5.99%-4.58%-7.14%
1 Year Performance-52.99%-8.09%-1.94%-7.46%

Galectin Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GALT
Galectin Therapeutics
1.938 of 5 stars
$2.91
-3.6%
$11.00
+278.0%
-51.5%$198.89MN/AN/A9
IMTX
Immatics
3.2106 of 5 stars
$6.37
-0.9%
$19.00
+198.3%
-33.6%$870.72M$54.60MN/A704
SNDX
Syndax Pharmaceuticals
2.421 of 5 stars
$9.38
-1.8%
$41.60
+343.5%
-46.4%$844.48M$172.35MN/A298
LXRX
Lexicon Pharmaceuticals
2.5507 of 5 stars
$1.89
+3.6%
$5.80
+207.7%
+21.9%$840.53M$49.80MN/A81
ALMS
Alumis
3.6616 of 5 stars
$6.37
-2.7%
$33.27
+422.3%
-13.1%$825.12M$24.05MN/A239

Related Companies and Tools


This page (NASDAQ:GALT) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners